Hepatic Metastasectomy for Testicular Germ Cell Tumors: Is it worth it?

You, Y. Nancy; Leibovitch, Bradley C.; Que, Florencia G.

doi:10.1007/s11605-009-0807-9

Cited by 15 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regardless, in patients where surgery is feasible, aggressive management appears justified, as our patients experienced a favorable 3-year estimated cancer-specific survival of 75%, despite liver metastasis usually being associated with a poor prognosis. Since our survival rate is similar to the reported experiences from other centers, our data further supports the potential for favorable survival outcomes after hepatic resection [16][17][18][19].…”

Section: Discussionsupporting

confidence: 90%

“…However, this 6% rate of histologic discordance is in marked contrast with the 21% seen in our study, as well as other reported experiences. For example, in a study from the Mayo clinic, among 15 patients undergoing hepatic resection for metastatic GCT [17], hepatic histology revealed teratoma or viable GCT in 38% (3/8) of patients with necrosis at extra-hepatic sites [17]. Furthermore, the German Testicular Cancer Study Group also reported a 39% discordance rate between hepatic and extrahepatic sites in 43 patients treated between 1990-1999 [18].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor

Pietzak

Assel

Becerra

et al. 2018

Urology

View full text Add to dashboard Cite

In this contemporary cohort, clinically significant discordance was observed between the histology of metastatic liver masses and that of retroperitoneal lymph nodes. The benefit of postchemotherapy liver mass resection for patients with advanced nonseminomatous GCT is supported by favorable survival outcomes. Until more reliable predictors of postchemotherapy histology exist, complete surgical resection of all sites of residual disease should be performed whenever feasible.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor

Pietzak

Assel

Becerra

et al. 2018

Urology

View full text Add to dashboard Cite

show abstract

“…Data on individual histologic subtypes frequently come from small case series [11][12][13][14][15][16][17][18][19]. Therefore, defining benefits of liver resection for individual patients is difficult [6].…”

Section: Introductionmentioning

confidence: 99%

The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review

Fitzgerald

Brinkley

Banks

et al. 2014

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

“…Surgery is used as an adjuvant treatment to eliminate residual tumours after chemotherapy or to select patients who will benefit from additional chemotherapy. In the study reported by You et al [50], 11 of the 15 patients were still alive 8 years after hepatectomy.…”

Section: Testicular Cancermentioning

confidence: 92%

The role of surgery in the management of liver metastases from non-colorectal cancers: A review of the literature

Armel Serge Kouame KOUASSI,

Ali KADA,

Mahmoud DABBAGH

et al. 2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Surgery for non-colorectal liver metastases is nowadays indicated due to advances in surgical techniques and patients multimodal management. The objective of our study is to evaluate the surgical management of liver metastases of non-colorectal cancers in the visceral surgery department of the Mohamed V military hospital in Rabat. This is a retrospective study on a series of 13 resections for non-colorectal liver metastases over a period of 6 years from January 2015 to December 2020. In our series, the average age is 53 years with a prevalence of women (62%). The primary cancer was ducal breast carcinoma 6 times (46.15%). There were 2 cases of stromal tumors (15.38%), 2 cases of neuroendocrine tumors (15.38%), one case of gastric adenocarcinoma, gastric small cell lymphoma, and of adrenocortical carcinoma. Liver metastases were synchronous in 76.92% of cases, metachronous in 23.08% of cases. They were unique in 84.62% of cases, bilobar in 15.38% of cases. The type of liver resection performed was 11 metastasectomy, 3 segmentectomy, 3 bi-segmentectomy. Mortality rate was zero and the morbidity rate was 15.38%. One patient had hepatic recurrence. With a follow-up of 3 to 36 months after resection, only one patient died after 12 months. The management of patients with non-colorectal liver metastases is based on a multimodal approach. Our results show that surgery, when feasible in selected patients, is a safe option and the only possibility for long-term survival. Future advances in chemotherapy, biotherapies and immunotherapy are likely to broaden the indications for surgery.

show abstract

Hepatic Metastasectomy for Testicular Germ Cell Tumors: Is it worth it?

Cited by 15 publications

References 24 publications

Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor

Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor

The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review

The role of surgery in the management of liver metastases from non-colorectal cancers: A review of the literature

Contact Info

Product

Resources

About